As a cardiology consultant in the hospital, here’s my nomination for the heroes of the pandemic:
1. Nurses in the ER
2. Nurses in the ICU
3. Nurses on the floor
4. Nurses in the dialysis clinic
5. Nurses in the...
Proof-of-concept for an entire new way to treat heart attack:
a gene editing medicine,
administered once in life,
safely turn off a gene -->
permanently lower cholesterol or triglycerides
A ‘Cure for Heart Disease’? A Single Shot Succeeds in Monkeys
Amazing.
Once weekly injection, 30lbs average weight loss
Phenomenal results for a medicine to treat obesity
Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM
Can we precisely rewrite the genetic code - make a single DNA spelling change - in the liver of a human being for clinical effect?
YES!
Scientific milestone: VERVE-101 provides first proof-of-concept for in vivo DNA base editing in humans
Clinical implication: It’s early…
Wow, say it with me:
“a functional cure” for sickle cell disease with CRISPR gene editing
All 31 patients with severe SCD, no vaso-occlusive crises (f/u 2 to 32 mos)
Similar durability and efficacy for beta-thal
👏🏽👏🏽👏🏽
@CRISPRTX
@VertexPharma
Does chronic disease need to equal chronic care? No
👇in
@Nature
from
@VerveTx
One-time base editing Rx (in vivo liver),
durable⬇️LDL-C
In monkeys:
*⬇️90% PCSK9,⬇️60% LDL-C, now out to 10 mos
* VERVE-101: efficacy at LNP doses as low as 0.5 mg/kg
Met with postdoc keen on staying in academia & applying for faculty jobs
I asked: "Have you put together a Description of Research Activities?"
👇🏽mine from April 2007 as I was just finishing my research training & applying for research faculty positions
Some thoughts...thread.
One-time treatment, permanent lowering of LDL, really?
Yes!
Today, we
@VerveTx
announce durable lowering of blood
PCKS9 protein (⬇️89%)
&
LDL-C (⬇️61%)
out to 6+ months after a one-time gene editing treatment in non-human primates
#JPM2021
Wow, antiviral pill taken within 3d of symptoms COVID: 89% reduction in hospitalization or death
Another
@pfizer
home run!
Protease inhibitor originally developed for SARS-Cov1 in 2003 and now repurposed!
A home run!
@intelliatweets
shows for first time in humans that in vivo liver gene editing (CRISPR-Cas9 mRNA + guide RNA packaged in a lipid nanoparticle)
is going to work (REALLY WELL)
At dose of just 0.3 mg/kg in 3 humans,
plasma TTR reductions:
80%, 84%, & 96%
No AEs
😳
News:
After 22y
@MassGeneralNews
@broadinstitute
understanding risk & resistance to heart attack,
I am moving to new role as CEO
@VerveTx
- a biotech we have founded
to develop gene editing Rx that permanently reduce risk of coronary disease in adults
Want something "unredacted" to read today
See here
Why am I so heavy?
Obesity largely viewed as disease of willpower or poor lifestyle choices
BUT…our research out today shows:
1. Genetics plays a large role in how heavy one gets...
Best news in months:
@Regeneron
"its scientists have now isolated hundreds of antibodies that neutralize virus, & they’re sorting through them — as well as antibodies isolated from ppl who have recovered from COVID-19 — to find best 2 with which to create a cocktail treatment"
Regeneron's sped up its timeline for human trials of antibody therapy for
#COVID19
by a couple months. Now aims to have doses for testing by early summer. George Yancopoulos: "There are always so many moving parts, but we’re hitting our best timelines"
Thrilled to announce that
@US_FDA
has cleared our
*investigational new drug (IND)* application
for VERVE-101
FDA reviewed our hold response which included:
1. interim clinical data from the ongoing heart-1 trial currently being conducted ex-U.S.
2. pre-clinical data to address
Wow (and a double Wow!).
*52 lb* weight loss (22.5%)
at highest dose of tirzepatide (a dual GLP-1 receptor / GIP receptor agonist from
@LillyPad
)
GLP-1 class truly going to revolutionize the treatment of obesity!!!
After being told of BRCA1 mutation,
up to 50% women opt for prophylactic mastectomy
Should this be so?
For "monogenic" forms breast ca, colorectal ca, & heart attack, we find polygenic background powerfully modifies risk
New on
@medrxivpreprint
In this pooled US cohort study, consumption of dietary cholesterol or eggs was associated with higher risk of incident CVD and all-cause mortality in a dose-response manner
#ACC19
“These are stunning results,” says gene editing researcher and cardiologist Kiran Musunuru of the University of Pennsylvania, who was not involved in the trial. “It exceeds all my expectations.”
Idea: 2016
Company: 2018
NHP data: 2020
1st patient dosed: 2022
1st human data for in vivo liver base editing in patients with heterozygous familial hypercholesterolemia and ASCVD
👇🏽
@American_Heart
@VerveTx
$VERV
Stay tuned!
When listening to a new consult presentation, 2 things I would love to hear *first*:
1. reason for consult
2. what brought pt to hospital
What I hear first most often:
82yo with CKD on HD, T2D, AAA s/p repair, s/p CABG, hyperlipidemia, HFrEF, PAF on Xarelto, COPD on home O2...
Intense hunt by biotech (i.e. Calico) & billionaires to promote lifespan (healthy aging).
Here, a genetic study reveals the secret: avoid a heart attack!
Most gene variants identified for lifespan are just common alleles *protective* for heart attack.
Wowza!
Losing 20lbs with GLP-1 agonist (semaglutide)
averts heart attacks/strokes
and
saves lives
(in patients who are overweight, without diabetes but with pre-existing atherosclerotic cardiovascular disease)
Grateful to
@American_Heart
for this wonderful honor - the Joseph A. Vita Award.
I had the opportunity to work with Dr. Vita as fellow at the Framingham Heart Study; he was a wonderful man and a terrific scientist.
New GLP1 Agonist orfoglipron
- once daily
- oral
- non-peptide
- no food or water restriction
2 Phase 2 trials
Weight: up to 14.7% weight loss
T2D: up to 2.1% hemoglobin A1C reduction
Spectacular new option in the works.
Best news of day (even better than event in DC)
Preliminary study from Sahin of
@BioNTech_Group
@pfizer
@BioNTech_Group
vaccine induced neutralizing antibody response to UK variant similar to wild-type COVID virus
👍🏽
Tweeps,
Thank you very much for kind words. Grateful to my family, mentors, trainees, institutions, and to this great country.
From immigration 1980 with my brother (L) to
#AHA17
honor of our scientific contributions yesterday (R).
A testament to power of opportunity in 🇺🇸
Having led company from my basement for the last 9 months 😳,
nice to visit our new
@VerveTx
offices in 500 Tech Square for first time...
👌🏽
@kendallnow
@ashishkjha
@bijans
Ashish,
once we get through this wave (let's say end Feb), I do wonder if we need to change our thinking re testing.
For endemic viruses (eg Flu), testing is typically done in people with symptoms (and usually just severe symptoms).
"healthy", then heart attack
Why?
Cool new study sheds light:
*9500 asymptomatic folks
*Test each with coronary CT angiogram (L)
*follow over time (R)
46% - atleast some heart artery blockages
5% - obstructive & extensive blockages!
Lots heart disease under radar
2018:
@VerveTx
founded with concept of one-time Rx to lower LDL as low as possible for as long as possible
Today: we are announcing
dosing of *first patient* with VERVE-101,
an in vivo CRISPR base editing medicine
🙏 to patient volunteer
$VERV
An oral drug which:
1. leads to meaningful weight loss
2. lowers all-cause mortality ~50%
3. lowers CV mortality
4. lowers hgA1C
Wow!
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM
👇🏽 what I hope will be our most impactful discovery to date
An enzyme whose loss of function lowers blood cholesterol & *protects* against fatty liver & cirrhosis
Kudos to
@connoremdin
whose clever analysis of public data (
@ukbiobank
) led to observation
If LDL⬇️for a long time, really hard to get heart attack
Cool new evidence
Some lucky people born with DNA variation that naturally lowers LDL
~50 mg/dl⬇️LDL, lifelong
&
risk for heart attack/death is ~50%⬇️!
So, for every 1 mg/dl⬇️LDL lifelong,
~1%⬇️risk heart attack/death
Quite an awesome email to wake up to:
About $10M worth of data to be given to you for free
*and*
the data generator is asking for input on file formats
👏🏽👏🏽
@uk_biobank
- emerging as the world standard for human biology research and open data
👇🏽
Unbelievable. 😱
The famous ‘Mediterranean diet’ is awesome study seems to have had serious randomization issues affecting >20% enrolled participants
Retracted and republished!
OK.
For all the people who think these trends are because the US has become taller:
🤦
average height US
1960: 5ft 8in (male); 5ft 3in (female)
2002: 5ft 9in (male); 5ft 4in (female)
What is inherited basis for heart attack?
A new quantitative (genome-wide polygenic score) that captures inherited liability to heart attack
Normal distribution in population
For those in top 8% of scores, 3-4-fold higher risk than all others
If you develop a once-&-done gene editing med to durably lower LDL cholesterol & Rx heart attack, what do you need?
Capital
Today,
@VerveTx
announces Series B fund raise of $94M led by
@Wellington_Mgmt
& co-led by
@cascapital
, with 9 new investors. 🙏
Often get asked about "founding story"
@VerveTx
None other than
@American_Heart
"One Brave Idea" competition to cure coronary heart disease
Our submission from April 2016 👇
Idea incubated with
@GVteam
'16-'18
Series A funding August '18
1st patient dosing - planned 2022
"Pfizer, Moderna, Johnson & Johnson, GlaxoSmithKline, Sanofi and possibly others"
Drugmakers are planning a public pledge to not send any Covid-19 vaccine to the FDA for review without extensive safety and efficacy data, sources say via
@business
You thought taking off your shoes was annoying.
How about a quick blood test before flying? 😱
Emirates becomes first airline to conduct on-site rapid COVID-19 tests for passengers
Happy Diwali 2020! 🪔
Diwali is a Hindu holiday which symbolizes the spiritual victory of light over darkness, good over evil, and knowledge over ignorance.
A new era of CRISPR-based medicines with single treatments that offer curative potential!
Kudos to
@VertexPharma
and
@CRISPRTX
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA
Amazing!
“After the CRISPR therapy, Gray’s total hemoglobin reached normal levels; of which 47% was fetal hemoglobin. It’s thought that a fetal hemoglobin level of 25%-30% is sufficient to “cure” a patient with sickle cell disease.“
New era of single, transformative therapies
Grateful to announce👇🏽
Thanks to
@GVteam
(lead),
@rtnarch
,
@FPrimeCapital
, Biomatics, Partners Innovation Fund
and 2 new investors Wellington &
@cascapital
Verve raises another $63m to develop gene-editing treatment for heart disease via
@BostonGlobe
👇🏽
First CRISPR-based medicine approved
Amazing new option for patients with sickle-cell disease & b-thal
MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia -
Terrific must-read
@TheLancet
on COVID-19 epidemiology
Did you know:
"A simple calculation gives fraction likely to be infected without mitigation. This fraction is roughly
1–1/R0. With R0 values for COVID-19 in China around 2·5...~60% of population would become
infected."
And it’s happening. Surreal.😊
@VerveTx
Amazing team developing gene editing medicines to solve the world’s leading of death, atherosclerotic cardiovascular disease
Cool new study from
@Regeneron
Identification loss-of-function variants in GPR75 gene that protect against obesity
Het LoF carriers about 12lb lighter.
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
Vertex and CRISPR Therapeutics showed their experimental therapy kept two sickle patients from experiencing painful incidences and kept patients with another blood disorder from requiring transfusions.
@ScottGottliebMD
key contributor to the sentinel surveillance of COVID-19 in Seattle was the Seattle Flu Study, a collaborative effort by the Brotman Baty Institute, UW Medicine, Fred Hutch, and Seattle Children’s
cc:
@JShendure
head Brotman Baty
So, I grew up in Tamilnadu, a state in southern India
Imagine my delight when my father sent me (L)
@VerveTx
shows up in Dinamalar, largest Tamil daily paper 😀
article (L), my father's translation (R)
boxed in white is "CRISPR gene editing" in Tamil!
@VerveTx
is thrilled to announce
*Clearance* of first VERVE-101 clinical trial application (CTA)
🎉🎉
Expect to treat 1st patient with HetFH in mid-2022
Expect clinical data in 2023
As part of planned global regulatory strategy,
CTA in UK & IND in US are up next
In
@CircAHA
, we publish today pre-clinical data for VERVE-101
Of note,
@American_Heart
tells us that for Scientific Sessions '22, this abstract the highest ranked one of all submitted from U.S.
#AHA22
Press release:
Paper:
GLP-1 agonists do seem to be the *miracle* drug for the 21st century obesity epidemic:
Lose weight, lower glucose, lower triglycerides, lower BP
*AND*
Lower risk of heart attack
Oh, also, potential benefits re NASH and sleep apnea
We are thrilled to gain
@EliLillyandCo
as a new partner for
@VerveTx
PCSK9 & ANGPTL3 programs👇
Lilly has purchased from
@BeamTx
all of their previously held product rights in PCSK9 & ANGPTL3 programs for a $600M total potential deal value.
For the PCSK9 & ANGPTL3 product…
2 powerful relationships in medicine:
(L) For every 39 mg/dL pharmacologic LDL lowering ~5y,
⬇️21% in CV events
(regardless starting LDL)
Now, we have:
(R) For every 5 mmHg pharmacologic BP lowering ~4y,
⬇️10% in CV events
(regardless starting BP)